Laboratory Biomarker Analysis

SEP 9, 2026 · PHASE 2 TRIAL

Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

ClinicalTrials.gov

This is a Phase 2 trial registry record with no results posted; the study is active but not recruiting, and outcome data are not yet reported in this source.

SEP 9, 2026 · PHASE 1/2 TRIAL

Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma

ClinicalTrials.gov

This is a Phase 1/2 trial registration with no results posted; it describes planned enrollment and endpoints only, without efficacy or safety outcomes, making it an early-stage design document rather than evidence of clinical benefit.

SEP 4, 2026 · PHASE 1 TRIAL

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

ClinicalTrials.gov

Phase 1b/II dose-escalation trial with planned enrollment and no results yet reported in this registry record; early-phase design focused on safety and maximum tolerated dose.

AUG 12, 2026 · PHASE 3 TRIAL

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

ClinicalTrials.gov

This is a clinical trial registry record describing a completed Phase 3 study design with planned enrollment of 305 participants; no results are reported in this registry entry, only the study structure and primary outcome measure.